This book provides a thorough update on the management of infections in patients with hematologic malignancies, focusing particularly on prevention, diagnosis, and treatment. Detailed attention is devoted to the central roles that vaccination and anti-infective prophylaxis have gained in improving overall survival in this patient group, in accordance with the principle that prevention is better than cure. Careful consideration is also paid to risk stratification, which is crucial in ensuring that anti-infective prophylaxis is targeted to those at the highest risk. While preventive strategies reduce the prevalence of infections, optimized management strategies are vital to decrease infection-related morbidity and mortality in those who nevertheless develop infections. Here, readers will find in-depth, up-to-date knowledge on the diagnosis and treatment of bacterial, fungal, viral, and parasitic infections, according to the affected organ and the causative pathogen. Finally, treatment in intensive care units is reviewed. The book will be of high value for hematologists, oncologists, and infection specialists.
|
1 Epidemiology and Risk Factors of Invasive Fungal Infections |
|
|
1 | (12) |
|
|
|
2 Antibacterial and Antiparasitic Prophylaxis |
|
|
13 | (10) |
|
|
|
|
|
|
|
23 | (14) |
|
|
|
|
|
|
|
|
|
37 | (12) |
|
|
|
|
|
5 Immune Response to Vaccines |
|
|
49 | (8) |
|
|
|
6 Vaccine-Preventable Diseases |
|
|
57 | (20) |
|
|
|
|
|
|
|
|
|
77 | (30) |
|
|
|
|
|
107 | (18) |
|
|
|
|
|
9 Antimicrobial Stewardship |
|
|
125 | (22) |
|
|
|
|
|
|
|
147 | (8) |
|
|
|
|
|
11 Gram-Positive Infections |
|
|
155 | (6) |
|
|
|
|
|
Francesco Giuseppe De Rosa |
|
|
12 Gram-Negative Infections |
|
|
161 | (20) |
|
|
|
|
|
|
|
|
|
181 | (10) |
|
|
|
|
|
|
|
14 Polyomavirus, Adenovirus, and Viral Respiratory Diseases |
|
|
191 | (30) |
|
|
|
|
|
|
|
|
|
221 | (20) |
|
|
|
|
|
|
|
241 | |
|
|
|
|
|
|
Oliver A. Cornely, MD, FACP, FIDSA, FAAM, FECMM, is Professor and Chair of Translational Research at the CECAD Institute of the University of Cologne, Germany. He is also Scientific Director of the Center for Clinical Trials and Professor of Internal Medicine and Consultant in Infectious Diseases at the Department I of Internal Medicine, University Hospital of Cologne. Prof. Cornely is board certified in internal medicine, infectious diseases, hematology, oncology, and emergency medicine. His research interest centers on infections in immunocompromised hosts. Prof. Cornely is a past President of the European Confederation of Medical Mycology. He currently serves on the Council of the International Society for Human and Animal Mycology and on the Board of Directors of the Mycoses Study Group Education and Research Consortium. He is founder and chair of the Infectious Diseases Scientific Working Group of the European Hematology Association. To date he has published over 600 peer-reviewed articles. He is an editorial board member for HemaSphere and Editor-in-Chief of Mycoses.
Martin Hoenigl, MD, Ass. Prof., FECMM, holds a faculty position at the Division of Infectious Diseases, University of California, San Diego (UCSD) and is a lecturer in the Section of Infectious Diseases and the Division of Pulmonology, Medical University of Graz, Austria. He obtained his venia docendi in internal medicine in 2012. Dr. Hoenigl has particular expertise in conducting research on clinical mycology, including fungal diagnostics and pharmacology of antifungal drugs and correlation with clinical findings. He is the current president of the European Confederation of Medical Mycology. He is also the founder of the ECMM Academy (together with Prof. Cornely) and since 2015 has served as an associate editor for the journal Mycoses. Dr. Hoenigl was awarded the Researcher of the Year award in 2011 at the Medical University of Graz, and in 2014 received the Research Promotion Award from the German Mycological Society. He is the author of over 200 PubMed-listed publications in the field of infectious diseases.
